4//SEC Filing
Hineline Lawrence J. 4
Accession 0000950170-24-021569
CIK 0001567514other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 8:00 PM ET
Size
20.6 KB
Accession
0000950170-24-021569
Insider Transaction Report
Form 4
Hineline Lawrence J.
VP of Finance, CFO & Secretary
Transactions
- Exercise/Conversion
Common Stock
2024-02-23+7,455→ 7,455 total - Sale
Common Stock
2024-02-26$68.33/sh−300$20,499→ 7,155 total - Sale
Common Stock
2024-02-26$69.38/sh−6,867$476,432→ 288 total - Sale
Common Stock
2024-02-26$70.15/sh−288$20,203→ 0 total - Exercise/Conversion
Common Stock
2024-02-26$36.89/sh+5,882$216,987→ 5,882 total - Sale
Common Stock
2024-02-26$69.47/sh−5,282$366,941→ 600 total - Sale
Common Stock
2024-02-26$69.81/sh−600$41,886→ 0 total - Exercise/Conversion
Restricted Stock Units
2024-02-23−7,455→ 0 total→ Common Stock (7,455 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-02-26−5,882→ 0 totalExercise: $36.89Exp: 2031-02-22→ Common Stock (5,882 underlying)
Footnotes (11)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F10]On February 23, 2021, the reporting person was granted 22,364 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F11]All shares underlying this option have vested.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.09 to $68.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.135 to $70.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.10 to $70.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F6]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the exercise of stock options.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.63 to $69.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.64 to $70.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F9]Each restricted stock unit represents a contingent right to receive one share of common stock.
Documents
Issuer
Intra-Cellular Therapies, Inc.
CIK 0001567514
Entity typeother
Related Parties
1- filerCIK 0001585697
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 8:00 PM ET
- Size
- 20.6 KB